ESH-iCML 14th International Conference Chronic Myeloid Leukemia: Biology and Therapy Organizers: JM Goldman, J. Cortes, T. Hughes September 20-23, 2012 – Baltimore, USA Inspired by the success of the 13th ESH-iCMLf events that took place in Estoril (Portugal) last year, the 2012 program will once again include a strong clinical component. The poster walks and small scientific workshops for non-clinical scientists that were so successful in 2011 will also be featured in Baltimore 2012. There will also be opportunities to organize corporate symposia in conjunction with the meeting 2012. Speakers at this meeting will present the newest and often unpublished data that relate to the (1) Biology of CML including the origin of BCR-ABL1, signal transduction, basis of disease progression, action of tyrosine kinase inhibitors and mechanisms underlying resistance to TKI, and (2) Aspects of treatment including prediction and definition of responses, drugs used in combination, molecular monitoring, targeting residual stem cells and approaches to cure. Clinical Content Many of those who attended the Washington DC meeting thought there should be more sessions addressing current clinical issues, such as choice of TKIs, molecular monitoring, defining responses, recognition of resistance, place of stem cell transplantation, etc and probably also more time for discussion. The Scientific Organizers are planning to implement these suggestions in Estoril. The title of meeting has therefore been changed from ‘Biological Basis of Therapy’, to ‘Biology and Therapy’. Program structure The number of oral presentations will be decreased and poster presentations will be more strongly emphasized than in previous years. There will be one session for oral presentation of outstanding posters and also a series of poster walks led by senior academics. Small scientific workshops led be postdoctoral researchers and requiring pre-registration will be a new addition to this year’s meeting. There will also be satellite symposia. Abstract submission (see instructions on separate page) We value greatly the flexibility of the programme whereby the final version is only available a few weeks before the meeting. We also value the fact that the ASH secretariat has agreed not to allow the presentation at our meeting to jeopardise acceptance for ASH in December. A list of participants’ publications, past and in press will be compiled and circulated to all participants before the meeting begins.
September 20-23, 2012 | Baltimore (Estados Unidos)